Recently, researchers reported that sulfarotene (WYC-209), an acyclic retinoid, overcame HCC resistance in a subset of cancer cells that were responsible for drug resistance (i.e., tumor-repopulating cells), possibly via RARα [217]. Here, RARA is linked to hepatocellular carcinoma.